Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.
Makers Laboratories financials and key ratios
Figures from the company's filings with NSE
In FY26 its consolidated net loss was ₹1.7 crore on revenue of ₹50.3 crore.
Makers Laboratories at a glance · consolidated
Free cash flow (FY26)
−₹2.3 Cr
EPS (FY26)
−₹2.91
Questions
What is the Makers Laboratories EPS?
Makers Laboratories' basic earnings per share (EPS) were −₹2.91 in FY26.
What is the Makers Laboratories free cash flow?
In FY26, Makers Laboratories generated ₹2 crore of cash from operations and spent ₹31 lakh on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹2.3 crore. In FY25 it was −₹4 crore.
What is the Makers Laboratories revenue and profit in FY26?
In FY26 (April 2025–March 2026), Makers Laboratories' consolidated net loss was ₹1.7 crore, on revenue from operations of ₹50.3 crore (up 17.2%).
How does Makers Laboratories compare with its peers?
On FY26 consolidated figures, against Jenburkt Pharmaceuticals: Makers Laboratories' operating margin of −4.1% is the lower of the two (Jenburkt Pharmaceuticals 23.8%; peer average 23.8%); its revenue growth over three years of 5.8% a year is the lower of the two (Jenburkt Pharmaceuticals 7.3% a year; peer average 7.3% a year).
Makers Laboratories vs Jenburkt Pharmaceuticals: how do they compare?
In FY26, Makers Laboratories earned net profit of ₹1.7 crore on revenue of ₹50.3 crore, against ₹34.7 crore on ₹169 crore for Jenburkt Pharmaceuticals. Makers Laboratories' operating margin was −4.1% (Jenburkt Pharmaceuticals 23.8%).
Where do these Makers Laboratories figures come from?
From Makers Laboratories' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
